Brookline Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities in the life sciences industry. The company was founded in 2020 and is based in New York, New York.
IPO Year: 2021
Exchange: NASDAQ
Website: brooklinecapitalacquisitioncorp.com
| Date | Price Target | Rating | Analyst |
|---|
SAN CARLOS, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Apexigen's Management will participate in the Brookline Capital Markets Newport Symposium, to be held in Newport, Rhode Island on Monday, July 18, 2022. Brookline Capital Markets Newport SymposiumFormat: Apexigen presentation and 1-on-1 meetingsDate: Monday, July 18, 2022Location: Newport, Rhode Island Please contact your Brookline Capital Markets sales representative for additional information. About Apexigen, Inc.Apexigen is a clinical-st
SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon
SAN CARLOS, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it will host an investor day to provide an overview of its antibody therapeutic pipeline and unique APXiMAB™ platform on Monday, May 16, 2022. The company will discuss lead asset sotigalimab's Phase 2 development program with a focus on melanoma, esophageal/GEJ cancer and sarcoma indications, its positioning in the competitive landscape, key data to date and upcoming milestones. The company will also highlight its promising preclinical program
- Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022
Brookline Capital Markets is hosting the Brookline Capital Markets Biotech Symposium today at the International Tennis Hall of Fame in Newport, Rhode Island. The theme of the meeting is "Transformative Biotech – Cancer, Rare Diseases, and Viruses." Participants include private and publicly traded biotechnology companies and a group of knowledgeable healthcare investors. The agenda includes company presentations in 1:1 and small group meetings along with relevant topical panels. Presenters include senior executives of leading biotechnology companies and key opinion leaders discussing advances in oncology, rare diseases, and infectious diseases. The Conference reflects Brookline's focus on
- Healthcare institutional investors and insiders commit $15 million through private investment in public equity ("PIPE") - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen's lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol "APGN" - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022
SAN CARLOS, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen" or the "Company"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of Meenu Karson as a member and Chair of Apexigen's Board of Directors, succeeding Kenneth Fong, Ph.D., as Chair. Ms. Karson will also be nominated to serve as a member and Chair of the Board of Directors of the combined company following the planned completion of the business combination with Brookline Capital Acquisition Corp. "It has been an honor to collaborate with the talented Apexigen team and guide the Comp
SAN CARLOS, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodon
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
4 - Apexigen, Inc. (0001814140) (Issuer)
SC 13G - Apexigen, Inc. (0001814140) (Subject)
SC 13G/A - Brookline Capital Acquisition Corp. (0001814140) (Subject)
SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)
SC 13G - Brookline Capital Acquisition Corp. (0001814140) (Subject)
Gainers Getty Images Holdings, Inc. (NYSE:GETY) shares climbed 149.1% to close at $26.15 on Friday following its merger with special-purpose acquisition company (SPAC) CC Neuberger Principal Holdings (CCNB). Brookline Capital Acquisition Corp. (NASDAQ:BCAC) gained 127.3% to settle at $22.71. AMTD Digital Inc. (NYSE:HKD) surged 122.4% to settle at $400.25 on continued post-IPO volatility. Senti Biosciences, Inc. (NASDAQ:SNTI) climbed 68.3% to close at $3.13 after declining 5% on Thursday. NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) gained 51.6% to close at $0.7930. The U.S. Food and Drug Administration (FDA) recently declined to issue an Emergency Use Authorization (EUA) for NRx Pharmaceu
During Friday's session, 61 companies made new 52-week lows. Areas of Interest About Today's 52-Week Lows: Verizon Communications (NYSE:VZ) was the biggest company in terms of market cap to set a new 52-week low. Kiora Pharmaceuticals (NASDAQ:KPRX) is the smallest company on a market cap basis to set a new 52-week low. VistaGen Therapeutics (NASDAQ:VTGN) saw the most significant move of the companies, as shares traded down 85.49% to reach its new 52-week low. Shapeways Hldgs (NYSE:SHPW) shares rebounded the highest, with shares trading up 0.16%, bouncing back after reaching its new 52-week low. During thn Friday, the following stocks set new 52-week lows: Verizon Communication
Brookline Capital Acquisition Corp. (“BCAC”) (NASDAQ:BCAC), a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, today announced that Brookline Capital Holdings, LLC, BCAC’s Sponsor, has deposited into the BCAC trust account (the “Trust Account”) an additional $167,032.54, representing $0.033 per public share. In consideration for the deposit, BCAC has issued to our Sponsor an amended unsecured interest free promissory note for the principal amount of the aggregate of such deposit, together with similar deposits made on May 2, 2022 and June 2, 2022, which will be repaid in connection with the closing of BCAC’s previously announced business combi
Apexigen, Inc. ("Apexigen"), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the appointment of William Duke as Chief Financial Officer, effective immediately. Mr. Duke is a biotech industry veteran and brings over 20 years of demonstrated success and leadership in corporate finance. "We are thrilled to welcome Bill. His deep financial expertise, broad strategic experience, demonstrated success raising capital and understanding of the life science industry make him the ideal fit for Apexigen's executive team," said Xiaodong Yang, M.D., Ph.D., Chief Executive Officer of Apexig
- Healthcare institutional investors and insiders commit $15 million through private investment in public equity (“PIPE”) - - Lincoln Park Capital has committed to purchase up to $50 million of common stock - - Proceeds to advance the Phase 2 development of Apexigen’s lead asset, sotigalimab, a CD40 agonist antibody with first-in-class and best-in-class potential - - Merger expected to be completed in July 2022; combined company expected to be listed on Nasdaq under the ticker symbol “APGN” - - Joint investor conference call to discuss the proposed transaction today, Friday, March 18, 2022 at 8:30 a.m. ET - SAN CARLOS, Calif. and NEW YORK, March 18, 2022 (GLOBE NEWSWIRE) -- Apexigen, In
10-Q - Apexigen, Inc. (0001814140) (Filer)
8-K - Apexigen, Inc. (0001814140) (Filer)
S-8 - Apexigen, Inc. (0001814140) (Filer)
EFFECT - Apexigen, Inc. (0001814140) (Filer)
EFFECT - Apexigen, Inc. (0001814140) (Filer)
424B3 - Apexigen, Inc. (0001814140) (Filer)
424B3 - Apexigen, Inc. (0001814140) (Filer)
S-1/A - Apexigen, Inc. (0001814140) (Filer)
S-1/A - Apexigen, Inc. (0001814140) (Filer)
8-K/A - Apexigen, Inc. (0001814140) (Filer)